Alphapharm

Company snapshot

Alphapharm has been developing and making generic medicines in Australia for almost 30 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, we’ve become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia’s leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines ar

• 127 approved product(s) across US/EU regulatory metadata.
• 30 active pipeline program(s) linked via ClinicalTrials.gov.
• 12 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Alphapharm. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Alphapharm.

1. Jun 8, 2026 Clinical update

   Debio0123-101 — Phase 1

2. Jun 8, 2026 Clinical update

   CLP24001 — Phase 1

3. Jun 8, 2026 Clinical update

   CLP22001 — Phase 1

4. Jun 8, 2026 Clinical update

   PTT101 — Phase 2

5. Jun 8, 2026 Clinical update

   Debio 0123-106 — Phase 1

View all clinical trial activity →

• What is Alphapharm?

  Alphapharm Pty is a pharma organization headquartered in AU. Primary therapeutic focus areas include Scabies, Bioequivalence trial in healthy volunteers, moderate to severely inflamed candidiasis of the skin, Mild to moderate atopic dermatitis, Papulopustular acne. NovaPharmaNews

• Is Alphapharm publicly traded?

  Alphapharm appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Alphapharm develop or market?

  We link 235 drug profile(s) where Alphapharm is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pharm-research-associates-uk-limited#company-drugs.

• What are the latest developments for Alphapharm?

  In the last 12 months our linked public records show 30 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Alphapharm focus on?

  Alphapharm focuses on Scabies, Bioequivalence trial in healthy volunteers, moderate to severely inflamed candidiasis of the skin based on our analysis of their pipeline programs and drug development activities.